HAEM5:Classic Hodgkin lymphoma: Difference between revisions
| [unchecked revision] | [pending revision] |
Bailey.Glen (talk | contribs) Created page with "{{DISPLAYTITLE:Classic Hodgkin lymphoma}} Haematolymphoid Tumours (5th ed.) {{Under Construction}} <blockquote class='blockedit'>{{Box-round|titl..." |
|||
| (26 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Classic Hodgkin lymphoma}} | {{DISPLAYTITLE:Classic Hodgkin lymphoma}} | ||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]] | |||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | |||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Lymphocyte-Rich Classic Hodgkin Lymphoma]]. | ||
Other relevent pages include: [[Nodular Sclerosis Classic Hodgkin Lymphoma]] | Other relevent pages include: [[HAEM4:Nodular Sclerosis Classic Hodgkin Lymphoma]] | ||
Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
}}</blockquote> | }}</blockquote> | ||
<span style="color:#0070C0">(General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)</span> | |||
==Primary Author(s)*== | |||
== | Xiaolin Hu, Ph.D., GeneDx | ||
==WHO Classification of Disease== | |||
Hodgkin | {| class="wikitable" | ||
!Structure | |||
!Disease | |||
|- | |||
|Book | |||
|Haematolymphoid Tumours (5th ed.) | |||
|- | |||
|Category | |||
|B-cell lymphoid proliferations and lymphomas | |||
|- | |||
|Family | |||
|Hodgkin lymphoma | |||
|- | |||
|Type | |||
|N/A | |||
|- | |||
|Subtype(s) | |||
|Classic Hodgkin lymphoma | |||
|} | |||
== | ==Related Terminology== | ||
{| class="wikitable" | {| class="wikitable" | ||
| | |+ | ||
| | |Acceptable | ||
|N/A | |||
|- | |- | ||
| | |Not Recommended | ||
| | |Hodgkin disease | ||
|} | |} | ||
== | ==Gene Rearrangements== | ||
No characteristic chromosomal rearrangements have been reported for lymphocyte-rich classical Hodgkin's lymphoma. | |||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
! | !Driver Gene!!Fusion(s) and Common Partner Genes!!Molecular Pathogenesis!!Typical Chromosomal Alteration(s) | ||
!Prevalence -Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | |||
!Established Clinical Significance Per Guidelines - Yes or No (Source) | |||
!Clinical Relevance Details/Other Notes | |||
|- | |- | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |||
|} | |} | ||
No characteristic chromosomal rearrangements have been reported for lymphocyte-rich classical Hodgkin's lymphoma. | No characteristic chromosomal rearrangements have been reported for lymphocyte-rich classical Hodgkin's lymphoma. | ||
==Individual Region Genomic Gain/Loss/LOH== | |||
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span> | |||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
! | !Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s) | ||
!Diagnostic Significance | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |||
|2p | |||
|gain | |||
|2p13 | |||
|REL | |||
|P | |||
|No | |||
|REL amplification promotes NF-κB signaling activation (PMID: 19380639) | |||
|- | |||
|9p | |||
|Gain | |||
|9p24.1 | |||
|CD274 (PD-L1), PDCD1LG2 (PD-L2), JAK2 | |||
|T, P | |||
|Yes (PMID:20628145) | |||
|9p24.1 amplification drives PD-L1/PD-L2 overexpression, relevant for immune checkpoint inhibitor therapy (PMID: 20628145, 27069084) | |||
|- | |||
|17p | |||
|Gain | |||
|17q21 | |||
|MAP3K14 | |||
|P | |||
|No | |||
|MAP3K14 (NIK) gain activates alternative NF-κB signaling (PMID: 19380639) | |||
|- | |- | ||
| | |6q | ||
|Loss | |||
| | |6q23-24 | ||
|TNFAIP3 | |||
|P | |||
|No | |No | ||
| | |Loss of TNFAIP3 (A20) disrupts NF-κB regulation (PMID: 19380639) | ||
|} | |||
|} | |||
There is no typical findings for lymphocyte-rich classical Hodgkin's lymphoma, the main features are also seen in other classical Hodgkin's lymphoma subtypes. | There is no typical findings for lymphocyte-rich classical Hodgkin's lymphoma, the main features are also seen in other classical Hodgkin's lymphoma subtypes. | ||
| Line 112: | Line 123: | ||
!Notes | !Notes | ||
|- | |- | ||
|2p <ref name=":4" /><ref name=":5">{{Cite journal|last=Steidl|first=Christian|last2=Telenius|first2=Adele|last3=Shah|first3=Sohrab P.|last4=Farinha|first4=Pedro|last5=Barclay|first5=Lorena|last6=Boyle|first6=Merrill|last7=Connors|first7=Joseph M.|last8=Horsman|first8=Douglas E.|last9=Gascoyne|first9=Randy D.|date=2010-07-22|title=Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome|url=https://pubmed.ncbi.nlm.nih.gov/20339089|journal=Blood|volume=116|issue=3|pages=418–427|doi=10.1182/blood-2009-12-257345|issn=1528-0020|pmid=20339089}}</ref> | |2p <ref name=":4">{{Cite journal|last=Wang|first=Hao-Wei|last2=Balakrishna|first2=Jayalakshmi P.|last3=Pittaluga|first3=Stefania|last4=Jaffe|first4=Elaine S.|date=2019-01|title=Diagnosis of Hodgkin lymphoma in the modern era|url=https://pubmed.ncbi.nlm.nih.gov/30407610|journal=British Journal of Haematology|volume=184|issue=1|pages=45–59|doi=10.1111/bjh.15614|issn=1365-2141|pmc=6310079|pmid=30407610}}</ref><ref name=":5">{{Cite journal|last=Steidl|first=Christian|last2=Telenius|first2=Adele|last3=Shah|first3=Sohrab P.|last4=Farinha|first4=Pedro|last5=Barclay|first5=Lorena|last6=Boyle|first6=Merrill|last7=Connors|first7=Joseph M.|last8=Horsman|first8=Douglas E.|last9=Gascoyne|first9=Randy D.|date=2010-07-22|title=Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome|url=https://pubmed.ncbi.nlm.nih.gov/20339089|journal=Blood|volume=116|issue=3|pages=418–427|doi=10.1182/blood-2009-12-257345|issn=1528-0020|pmid=20339089}}</ref> | ||
|Gain | |Gain | ||
| | | | ||
| Line 175: | Line 186: | ||
| | | | ||
|} | |} | ||
==Characteristic Chromosomal Patterns== | |||
==Characteristic Chromosomal or Other Global Mutational Patterns== | |||
Put your text here and fill in the table <span style="color:#0070C0">(I''nstructions: Included in this category are alterations such as hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis; microsatellite instability; homologous recombination deficiency; mutational signature pattern; etc. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span> | |||
{| class="wikitable sortable" | |||
|- | |||
!Chromosomal Pattern | |||
!Molecular Pathogenesis | |||
!Prevalence - | |||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | |||
!Established Clinical Significance Per Guidelines - Yes or No (Source) | |||
!Clinical Relevance Details/Other Notes | |||
|- | |||
|<span class="blue-text">EXAMPLE:</span> | |||
Co-deletion of 1p and 18q | |||
|<span class="blue-text">EXAMPLE:</span> See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). | |||
|<span class="blue-text">EXAMPLE:</span> Common (Oligodendroglioma) | |||
|<span class="blue-text">EXAMPLE:</span> D, P | |||
| | |||
| | |||
|- | |||
|<span class="blue-text">EXAMPLE:</span> | |||
Microsatellite instability - hypermutated | |||
| | |||
|<span class="blue-text">EXAMPLE:</span> Common (Endometrial carcinoma) | |||
|<span class="blue-text">EXAMPLE:</span> P, T | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|} | |||
No characteristic chromosomal patterns have been reported for lymphocyte-rich classical Hodgkin's lymphoma. | No characteristic chromosomal patterns have been reported for lymphocyte-rich classical Hodgkin's lymphoma. | ||
| Line 187: | Line 233: | ||
!Notes | !Notes | ||
|- | |- | ||
| | |Aneuploidy, hypertetraploidy | ||
|No | |||
|unkonwn | |||
|unknown | |||
|Common in HRS cells; contributes to genomic instability (PMID: 7632954) | |||
|} | |||
==Gene Mutations (SNV/INDEL)== | |||
|Yes | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent or common as well either disease defining and/or clinically significant. If a gene has multiple mechanisms depending on the type or site of the alteration, add multiple entries in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Details on clinical significance such as prognosis and other important information such as concomitant and mutually exclusive mutations can be provided in the notes section. Please include references throughout the table. Do not delete the table.'') </span> | ||
{| class="wikitable sortable" | |||
|- | |||
!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence - | |||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | |||
!Established Clinical Significance Per Guidelines - Yes or No (Source) | |||
!Clinical Relevance Details/Other Notes | |||
|- | |||
|TNFAIP3 | |||
|Inactivating mutation | |||
|Tumor Suppressor Gene | |||
|Recurrent (5-20%) | |||
|P | |||
|No | |||
|Loss of function mutations disrupt NF-κB regulation (PMID: 19380639) | |||
|- | |||
|SOCS1 | |||
|Frameshift and nonsense mutations | |||
|Tumor Suppressor Gene | |||
|Recurrent (5-20%) | |||
|P | |||
|No | |||
|SOCS1 mutations activate JAK/STAT signaling (PMID: 24531327) | |||
|- | |||
|STAT6 | |||
|Missense mutations | |||
|Oncogene | |||
|Recurrent (5-20%) | |||
|P | |||
|No | |||
|STAT6 mutations drive cytokine signaling alterations (PMID: 24531327, 29650799) | |||
|- | |||
|B2M | |||
|Inactivating mutations | |||
|Tumor Suppressor Gene | |||
|Rare (<5%) | |||
|P | |||
|No | |||
|Loss of MHC class I expression aids immune evasion (PMID: 21368758) | |||
|- | |||
|CIITA | |||
|Inactivating mutations | |||
|Tumor Suppressor Gene | |||
|Rare (<5%) | |||
|P | |||
|No | |No | ||
|Loss of MHC class II expression aids immune evasion (PMID: 21368758) | |||
|- | |||
|XPO1 | |||
|Missense mutations | |||
|Oncogene | |||
|Rare (<5%) | |||
|Unknown | |||
|No | |No | ||
| | |Emerging evidence of role in CHL pathogenesis (PMID: 33686198) | ||
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | |||
|} | |||
No characteristic gene mutations have been reported for lymphocyte-rich classical Hodgkin's lymphoma. | No characteristic gene mutations have been reported for lymphocyte-rich classical Hodgkin's lymphoma. | ||
| Line 203: | Line 303: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Gene; Genetic Alteration!! | !Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations | ||
! | !Diagnostic Significance (Yes, No or Unknown) | ||
!Prognostic Significance (Yes, No or Unknown) | !Prognostic Significance (Yes, No or Unknown) | ||
!Therapeutic Significance (Yes, No or Unknown) | !Therapeutic Significance (Yes, No or Unknown) | ||
!Notes | !Notes | ||
|- | |- | ||
|EXAMPLE: TP53; Variable LOF mutations | |<span class="blue-text">EXAMPLE:</span> TP53; Variable LOF mutations | ||
EXAMPLE: | <span class="blue-text">EXAMPLE:</span> | ||
EGFR; Exon 20 mutations | EGFR; Exon 20 mutations | ||
EXAMPLE: BRAF; Activating mutations | <span class="blue-text">EXAMPLE:</span> BRAF; Activating mutations | ||
|EXAMPLE: TSG | |<span class="blue-text">EXAMPLE:</span> TSG | ||
|EXAMPLE: 20% (COSMIC) | |<span class="blue-text">EXAMPLE:</span> 20% (COSMIC) | ||
EXAMPLE: 30% (add Reference) | <span class="blue-text">EXAMPLE:</span> 30% (add Reference) | ||
|EXAMPLE: IDH1 R123H | |<span class="blue-text">EXAMPLE:</span> IDH1 R123H | ||
|EXAMPLE: EGFR amplification | |<span class="blue-text">EXAMPLE:</span> EGFR amplification | ||
| | | | ||
| | | | ||
| | | | ||
|EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference). | |<span class="blue-text">EXAMPLE:</span> Excludes hairy cell leukemia (HCL) (add reference). | ||
<br /> | <br /> | ||
|} | |} | ||
| Line 232: | Line 332: | ||
==Epigenomic Alterations== | ==Epigenomic Alterations== | ||
Global downregulation of B-cell transcription factors (OCT2, BOB1, PU.1) and epigenetic silencing of B-cell program genes (PMID: 19465900, 14694522) | |||
==Genes and Main Pathways Involved== | ==Genes and Main Pathways Involved== | ||
| Line 241: | Line 341: | ||
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | ||
|- | |- | ||
| | |REL, TNFAIP3, NFKBIA, MAP3K14 | ||
| | |NF-κB signaling | ||
| | |Constitutive activation of classical and alternative NF-κB pathways promotes HRS cell survival (PMID: 19380639, 33686198) | ||
|- | |- | ||
| | |JAK2, STAT6, SOCS1 | ||
| | |JAK/STAT signaling | ||
| | |Dysregulation leads to proliferation and survival of HRS cells (PMID: 24531327, 29650799) | ||
|- | |- | ||
| | |CD274 (PD-L1), PDCD1LG2 (PD-L2), B2M | ||
| | |Immune evasion | ||
| | |Upregulation of PD-L1/PD-L2 and loss of MHC I/II expression enables immune escape (PMID: 20628145, 21368758) | ||
|- | |- | ||
| | |EBV LMP1, LMP2A | ||
| | |Viral oncogenesis | ||
|LMP1 mimics CD40 signaling, LMP2A mimics BCR signaling to promote HRS cell survival in EBV+ CHL (PMID: 9501091, 17682125) | |||
|- | |||
| | |||
| | | | ||
| | | | ||
|} | |} | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||
*Immunohistochemistry for CD30, CD15, PAX5, and EBV (EBER in situ hybridization) (PMID: 2477085, 6946981) | |||
*9p24.1 copy number assessment (FISH or NGS) may be used in refractory/relapsed cases to evaluate PD-L1/PD-L2 amplification for potential immunotherapy (PMID: 29394125). | |||
*TR clonality assays can help exclude T-cell lymphomas in challenging differential diagnoses (PMID: 24128129). | |||
*Targeted NGS panels for NF-κB and JAK/STAT pathway mutations (PMID: 33686198) | |||
==Familial Forms== | ==Familial Forms== | ||
Familial aggregation and monozygotic twin concordance suggest genetic predisposition (PMID: 26311361, 34208754) | |||
==Additional Information== | ==Additional Information== | ||
| Line 275: | Line 378: | ||
==Links== | ==Links== | ||
Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span> | |||
==References== | ==References== | ||
<references /> | <references /> | ||
| Line 287: | Line 390: | ||
<nowiki>*</nowiki>''Citation of this Page'': “Classic Hodgkin lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Classic_Hodgkin_lymphoma</nowiki>.[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases C]] | <nowiki>*</nowiki>''Citation of this Page'': “Classic Hodgkin lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Classic_Hodgkin_lymphoma</nowiki>. | ||
[[Category:HAEM5]] | |||
[[Category:DISEASE]] | |||
[[Category:Diseases C]] | |||